Mondobiotech Holding AG Company presentation

More documents

Recommendations

Info

Scientific Snapshot Information: DK-0249-01 §� TB is a contagious airborne disease caused by infection of the lungs with Mycobacterium tuberculosis (Mtb). In Multidrug-Resistant Tuberculosis (MDR TB) the bacteria can no longer be killed by at least the two best antibiotics, isoniazid (INH) and rifampin (RIF) taken for six months to two years. §� Mechanism of Action: DK-0249 is synonymous for five synthetically-produced small peptides which act via direct anti-mycobacterial killing. They are currently in the final candidate selection phase. §� Key data (in vitro efficacy data): Dose-responsive inhibition of growth of the best characterized strain of TB by various MPC candidates: 50
Products licensed DasKloster 1001-01 Idiopathic Pulmonary Fibrosis (IPF) InterMune Inc. DasKloster 1000-01 Pulmonary Arterial Hypertension (PAH) Biogen Idec Inc. & Lung Rx, LLC DasKloster 1000-02 Sarcoidosis Lung Rx, LLC DasKloster 1000-03 Idiopathic Pulmonary Fibrosis (IPF) Lung Rx, LLC DasKloster 1000-04 Acute Respiratory Distress Syndrome (ARDS/ALI) Lung Rx, LLC DasKloster 0138-01 Methicillin-Resistant Staphylococcus Aureus in Cystic Fibrosis Lung Rx, LLC Lung Rx, a wholly-owned subsidiary of United Therapeutics (Nasdaq: UTHR), has acquired the Aviptadil platform in January 2010 and returned it to mondoBIOTECH on May 2011 due to strategic reasons In development Ready for licensing Licensed 51
Page 1 and 2: Mondobiotech Holding AG Company pre
Page 3 and 4: mondoBIOTECH at a glance • Headqu
Page 5 and 6: Board of Directors Robert Edward Pa
Page 7 and 8: Our approach to drug discovery •
Page 9 and 10: Introduction to the Search&Match me
Page 11 and 12: The Model • Knowledge from litera
Page 13 and 14: The Search and Match Software Platf
Page 15 and 16: Match • Any path through the know
Page 17 and 18: Match - a multi-technique approach
Page 19 and 20: Bio-Mathematical Technology Platfor
Page 21 and 22: Match - Project DK-0112-01 21
Page 23 and 24: Match - Project DK-1001-01 23
Page 25 and 26: MPC Validation: the mondoBIOTECH Co
Page 27 and 28: Set up of new projects PROJECT SET
Page 29 and 30: Intellectual Property Strategy & Cu
Page 31 and 32: mondoBIOTECH’s IP Strategy Two in
Page 33 and 34: mondoBIOTECH’s IP Strategy: Two I
Page 35 and 36: Orphan Drug Designations 10 Granted
Page 37 and 38: Why Peptides Peptides characteristi
Page 40 and 41: Diversifying the Risk in Drug Disco
Page 42 and 43: Current Pipeline DasKloster 1000-01
Page 46: Scientific Snapshot Information: DK
Page 49: Scientific Snapshot Information: DK
Page 53 and 54: Licensed Products • Aviptadil pla
Page 55: mondoBIOTECH holding AG DasKloster

Mondobiotech Holding AG Company presentation

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?